Sunesis Pharmaceuticals (NASDAQ:SNSS) Earns Media Impact Rating of 0.21
News articles about Sunesis Pharmaceuticals (NASDAQ:SNSS) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sunesis Pharmaceuticals earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.0637200596423 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Sunesis Pharmaceuticals: Sns-062 Trial Up And Running – Investing.com (investing.com)
- Sunesis Pharmaceuticals Inc (SNSS) Shares Moving On Volume – Stock Press Daily (stockpressdaily.com)
- FY2017 EPS Estimates for Sunesis Pharmaceuticals, Inc. Increased by Cantor Fitzgerald (SNSS) (americanbankingnews.com)
- Investors Keen on a Bargain are Looking at Sunesis … – FLBC News – FLBC News (flbcnews.com)
- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
Several analysts recently issued reports on the company. Zacks Investment Research upgraded Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Cantor Fitzgerald restated a “hold” rating and issued a $3.00 price target on shares of Sunesis Pharmaceuticals in a research note on Thursday, July 27th.
Sunesis Pharmaceuticals (NASDAQ SNSS) traded up 0.40% during mid-day trading on Tuesday, reaching $2.48. The company had a trading volume of 77,603 shares. Sunesis Pharmaceuticals has a 12-month low of $2.40 and a 12-month high of $6.30. The company’s market capitalization is $58.31 million. The stock has a 50-day moving average of $2.69 and a 200 day moving average of $3.48.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.76) by $0.35. During the same period in the previous year, the company earned ($0.12) earnings per share. On average, analysts expect that Sunesis Pharmaceuticals will post ($1.61) EPS for the current year.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.